Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Beginner level


Long-term Activity Ratios (Summary)

Eli Lilly & Co., long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net fixed asset turnover 2.88 2.92 2.83 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 2.53 2.55 2.51 2.48
Total asset turnover 0.55 0.56 0.57 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 0.55 0.56 0.58 0.56
Equity turnover 5.61 7.50 8.56 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 1.34 1.41 1.34 1.37

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Net Fixed Asset Turnover

Eli Lilly & Co., net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 5,499,400  5,859,800  6,114,000  5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700 
Property and equipment, net of accumulated depreciation 7,981,100  7,897,900  7,872,900  7,801,500  7,847,500  7,780,000  8,919,500  8,814,100  8,770,800  8,958,200  8,826,500  8,598,500  8,582,800  8,425,500  8,252,600  8,251,900  8,066,100  8,033,100  8,053,500  8,075,300  8,022,600  7,950,700 
Long-term Activity Ratio
Net fixed asset turnover1 2.88 2.92 2.83 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 2.53 2.55 2.51 2.48
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 3.77 4.06 3.97 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 3.61 3.53 3.49 3.56
AbbVie Inc. 7.38 11.50 11.23 11.36 11.33 11.42 11.36 10.91 11.10 10.47 10.07 10.11 10.05 10.04 9.85 9.57 9.46 9.16 8.91
Amgen Inc. 4.78 4.68 4.51 4.55 4.58 4.59 4.54 4.51 4.48 4.44 4.37 4.45 4.41 4.41 4.41 4.39 4.41 4.36 4.27
Biogen Inc. 4.35 4.39 4.43 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86 3.95 4.14 4.42 4.58 4.78 4.88 4.84 4.92
Bristol-Myers Squibb Co. 6.03 5.07 4.18 5.00 4.92 4.67 4.49 4.33 4.25 4.16 4.15 4.10 4.09 3.98 3.90 3.86 3.83 3.80 3.75
Gilead Sciences Inc. 4.70 4.90 4.91 5.03 5.16 5.31 5.41 5.76 6.23 7.11 7.79 8.72 9.31 9.80 10.45 11.48 12.29 13.34 14.13
Illumina Inc. 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36 3.74 4.52 5.85 6.48
Johnson & Johnson 4.57 4.75 4.65 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 4.45 4.44 4.40 4.41
Merck & Co. Inc. 2.99 3.15 3.11 3.22 3.20 3.19 3.18 3.27 3.27 3.24 3.23 3.27 3.31 3.32 3.31 3.32 3.29 3.19 3.16
Pfizer Inc. 3.49 3.61 3.71 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 4.01 3.84 3.75 3.55
Regeneron Pharmaceuticals Inc. 2.64 2.71 2.72 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 2.53 2.62 2.66 2.57
Vertex Pharmaceuticals Inc. 7.42 6.55 5.59 4.93 4.72 4.40 3.75 3.50 3.21 3.02 3.15 3.02 2.88 2.85 2.44 2.42 2.26 1.87 1.48
Zoetis Inc. 3.15 3.21 3.23 3.39 3.48 3.51 3.51 3.68 3.80 3.75 3.70 3.69 3.70 3.62 3.54 3.53 3.62 3.66 3.65

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

1 Q2 2020 Calculation
Net fixed asset turnover = (RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019 + RevenueQ3 2019) ÷ Property and equipment, net of accumulated depreciation
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 7,981,100 = 2.88

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.

Total Asset Turnover

Eli Lilly & Co., total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 5,499,400  5,859,800  6,114,000  5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700 
Total assets 41,967,000  41,102,800  39,286,100  37,893,100  38,666,400  38,006,800  43,908,400  44,625,100  42,359,200  44,355,600  44,981,000  43,010,400  40,946,500  37,624,300  38,805,900  37,590,300  36,475,300  34,691,800  35,568,900  36,304,700  36,036,600  35,653,900 
Long-term Activity Ratio
Total asset turnover1 0.55 0.56 0.57 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 0.55 0.56 0.58 0.56
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.46 0.48 0.47 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 0.52 0.52 0.51 0.49
AbbVie Inc. 0.24 0.37 0.37 0.55 0.57 0.58 0.55 0.49 0.50 0.43 0.40 0.40 0.40 0.40 0.39 0.38 0.37 0.44 0.43
Amgen Inc. 0.36 0.37 0.37 0.37 0.38 0.35 0.34 0.33 0.33 0.31 0.27 0.27 0.28 0.28 0.28 0.28 0.29 0.28 0.29
Biogen Inc. 0.57 0.55 0.53 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52 0.51 0.54 0.54 0.50 0.52 0.52 0.53 0.55
Bristol-Myers Squibb Co. 0.27 0.24 0.20 0.42 0.43 0.67 0.64 0.65 0.66 0.64 0.62 0.61 0.61 0.61 0.58 0.55 0.54 0.53 0.52
Gilead Sciences Inc. 0.39 0.37 0.36 0.37 0.35 0.35 0.34 0.34 0.35 0.37 0.37 0.42 0.47 0.50 0.53 0.55 0.64 0.68 0.62
Illumina Inc. 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56 0.56 0.58 0.59 0.60
Johnson & Johnson 0.51 0.53 0.52 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 0.51 0.51 0.52 0.53
Merck & Co. Inc. 0.52 0.57 0.55 0.55 0.53 0.52 0.51 0.49 0.49 0.47 0.46 0.43 0.43 0.41 0.42 0.41 0.41 0.40 0.39
Pfizer Inc. 0.28 0.30 0.31 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 0.30 0.31 0.31 0.29
Regeneron Pharmaceuticals Inc. 0.55 0.51 0.53 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 0.69 0.75 0.75 0.73
Vertex Pharmaceuticals Inc. 0.53 0.54 0.50 0.48 0.49 0.50 0.49 0.61 0.60 0.61 0.70 0.72 0.65 0.69 0.59 0.64 0.61 0.52 0.41
Zoetis Inc. 0.49 0.55 0.54 0.55 0.55 0.54 0.54 0.55 0.65 0.63 0.62 0.55 0.64 0.65 0.64 0.63 0.65 0.65 0.60

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

1 Q2 2020 Calculation
Total asset turnover = (RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019 + RevenueQ3 2019) ÷ Total assets
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 41,967,000 = 0.55

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Equity Turnover

Eli Lilly & Co., equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue 5,499,400  5,859,800  6,114,000  5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700 
Total Eli Lilly and Company shareholders’ equity 4,092,900  3,078,800  2,606,900  3,382,500  2,780,500  2,480,300  9,828,700  13,076,600  11,555,200  14,527,000  11,592,200  14,890,300  14,100,800  14,031,000  14,007,700  15,589,200  14,637,300  15,009,900  14,571,300  15,221,400  14,670,300  14,919,800 
Long-term Activity Ratio
Equity turnover1 5.61 7.50 8.56 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 1.34 1.41 1.34 1.37
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.03 1.06 1.03 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 1.00 0.99 0.98 0.96
AbbVie Inc. 2.46 8.33 5.54 4.08 4.44 5.25 5.53 3.90 4.39 5.12 5.79
Amgen Inc. 2.17 2.41 2.30 2.04 2.07 2.07 1.80 1.54 1.48 1.40 0.86 0.68 0.69 0.71 0.73 0.70 0.72 0.74 0.75
Biogen Inc. 1.28 1.15 1.08 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97 0.92 1.01 1.00 0.94 0.94 0.99 1.06 1.15
Bristol-Myers Squibb Co. 0.71 0.62 0.51 1.37 1.49 1.53 1.61 1.62 1.75 1.64 1.77 1.39 1.38 1.38 1.20 1.18 1.18 1.18 1.16
Gilead Sciences Inc. 1.21 1.01 0.98 1.07 0.97 1.00 1.01 0.96 1.05 1.18 1.26 1.09 1.24 1.40 1.59 1.85 2.06 2.42 1.73
Illumina Inc. 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09 1.06 1.13 1.13 1.20
Johnson & Johnson 1.28 1.35 1.38 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 0.98 0.98 0.97 0.98
Merck & Co. Inc. 1.71 1.83 1.81 1.71 1.61 1.56 1.58 1.29 1.27 1.21 1.17 1.04 1.01 1.00 0.99 0.91 0.91 0.90 0.88
Pfizer Inc. 0.76 0.78 0.82 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 0.84 0.83 0.81 0.75
Regeneron Pharmaceuticals Inc. 0.88 0.66 0.71 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 1.05 1.14 1.18 1.12
Vertex Pharmaceuticals Inc. 0.72 0.75 0.68 0.69 0.68 0.69 0.69 0.97 0.98 1.01 1.23 1.28 1.28 1.35 1.47 1.63 1.59 1.35 1.10
Zoetis Inc. 2.13 2.30 2.31 2.30 2.51 2.55 2.67 2.70 2.84 2.78 3.00 2.58 2.93 3.08 3.29 3.08 3.58 4.14 4.46

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

1 Q2 2020 Calculation
Equity turnover = (RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019 + RevenueQ3 2019) ÷ Total Eli Lilly and Company shareholders’ equity
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 4,092,900 = 5.61

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.